42 results on '"Sattler, Martin"'
Search Results
2. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
3. Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach
4. Targeting Mcl-1 for multiple myeloma (MM) therapy: Drug-induced generation of Mcl-1 fragment Mcl-1128–350 triggers MM cell death via c-Jun upregulation
5. Rac2-MRC-cIII–generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors
6. BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair
7. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes
8. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species
9. Targeting c-Kit mutations: basic science to novel therapies
10. 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells
11. Critical role for Gab2 in transformation by BCR/ABL
12. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration
13. JAK2 Gets Hi stone H3 Rolling
14. The BCR/ABL Oncogene Alters the Chemotactic Response to Stromal-Derived Factor-1α
15. Hematopoietic Growth Factors Signal Through the Formation of Reactive Oxygen Species
16. Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs for Multiple Myelioma Therapy
17. Multiple Myeloma Pathogenesis: The Role of Junb in Bone Marrow Angiogenesis
18. Combined targeting of distinct c-Myc and JunB transcriptional programs for multiple myeloma therapy
19. Identification of Wee1 and IGF-1R As Novel Therapeutic Targets for Mutant RAS-Driven Acute Leukemia By Combinatory Chemical Screens
20. The AP-1 Transcription Factor JunB Promotes Multiple Myeloma (MM) Cell Proliferation, Survival and Drug Resistance in the Bone Marrow Microenvironment
21. BCR-ABL Transformation Requires Glycogen Synthase 1 (GYS1) Expression for Cell Growth and Increased Glycogen Production
22. The Role of the ABL1/YAP1/P73 Axis in Prevention of DNA Damage-Mediated Apoptosis in Multiple Myeloma
23. Targeting Rac2 - Mitochondrial Respiratory Chain Complex III Signaling to Prevent Genomic Instability in Leukemia Stem and Progenitor Cells
24. Kinase Domain Mutations in JAK2V617F Confer Resistance to the Novel JAK2 Inhibitor Ruxolitinib
25. Functional Oncogene Identification in Patient Leukemia Samples.
26. Novel Transforming Mutations of CBL in Human Acute Myeloid Leukemia
27. Mcl-1 Fragment Mcl-1(128–350) Induces Inhibition of Multiple Myeloma Cell Proliferation and Apoptosis Via Both Upregulation of C-Jun as Well as Modulation of Its Transcriptional Activity
28. C-Myc- Dependent Stabilization of Hif-1alpha in MM: Therapeutic Implications
29. BCR-ABL Induces Error-Prone Single Strand Annealing in Transformed Cells.
30. The Tyrophostin Adaphostin (NSC680410) Inhibits Multiple Myeloma Bone Marrow Angiogenesis In Vitro and In Vivo.
31. SB1518: A Potent and Orally Active JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders.
32. The Jak2 V617F Oncogene Associated with Polycythemia Vera Requires a Functional FERM Domain for Transformation and for Expression of the Myc and Pim Proto-Oncogenes.
33. Upregulation of c-Jun Induces Cell Death Via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma.
34. The Small-Molecule VEGF-Receptor Inhibitor Pazopanib (GW786034B) Targets Both Tumor and Endothelial Cells in Multiple Myeloma.
35. A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples
36. Targeting Src- Family Kinase Activation and Downstream Molecular Events To Overcome MM Cell Growth, Survival, and Drug- Resistance.
37. Up-Regulation of c-Jun contributes to the Induction of Apoptosis by Adaphostin in Human Multiple Myeloma Cells.
38. Mitochondria and Caspase-Independent Cell-Death Triggered by GCS-100, a Novel Carbohydrate-Based Therapeutic in Multiple Myeloma (MM) Cells.
39. Caveolin-1 Is Required for VEGF- Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib (Velcade®).
40. Pim Kinases Mediate Viability Signals Downstream of the Tyrosine Kinase Oncogenes BCR-ABL and FLT3-ITD.
41. How to interfere with FLT3
42. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.